Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Trivalent Vaccine (CHO Cell) LYB002 in Chinese Adults 18 Years and Above Completed Three-dose Inactivated COVID-19 Vaccine

NCT05928468 is registered in ClinicalTrials.gov with Guangzhou Patronus Biotech Co., Ltd. as lead sponsor.

NCT NCT05928468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05928468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Trivalent Vaccine (CHO Cell) LYB002 in Chinese Adults 18 Years and Above Completed Three-dose Inactivated COVID-19 Vaccine
Lead sponsor
Guangzhou Patronus Biotech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 25, 2023
Completion date
November 30, 2023
Enrollment
210 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19